Temozolomide Comment.pdf (60.01 kB)
Download fileGoing Past the Data for Temozolomide
journal contribution
posted on 2012-06-27, 00:00 authored by J. Lee Villano, Nathalie Letarte, Linda R. BresslerThe benefit of six cycles of adjuvant temozolomide was documented in a
randomized phase III (EORTC‐NCIC CE.3) trial and this therapy, following combined
temozolomide and radiation, is the standard of care for patients with newly
diagnosed glioblastoma. We comment on the differences on length of adjuvant
therapy in both clinical practice and national studies (e.g. RTOG 0825), usually
doubling the length than in the EORTC/NCIC study, and relate to historic adjuvant
trials for solid tumors.
History
Publisher Statement
© 2012 by Springer Verlag, Cancer Chemotherapy and Pharmacology The original publication is available at www.springerlink.com DOI: 10.1007/s00280-011-1796-4Publisher
Springer VerlagLanguage
- en_US